We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Non-Invasive COVID-19 Test Identifies `Breath Signatures` to Provide Almost Instant Results

By LabMedica International staff writers
Posted on 29 Oct 2020
Initial findings from a new study have shown how COVID-19 can be detected via a non-invasive breath test by identifying candidate biomarkers, providing almost instant results.

The new study was conducted by Loughborough University (Leicestershire, UK) which is part of a consortium’s research team that has been able to identify candidate biomarkers present in the breath of someone affected by COVID-19. More...
Utilizing technologies which were developed earlier, the team has demonstrated how these markers or ‘breath signatures’ can be used to rapidly distinguish COVID-19 from other respiratory conditions at point of need, such as an emergency department, a workplace or a care setting, with no laboratory support. The IMSPEX Group which is also part of the consortium will be working alongside researchers to help develop and scale such technology. Its BreathSpec device has been a key tool used by researchers in the analysis of volatile organic compounds (VOCs) in human breath.

For the feasibility study, the researchers recruited 98 patients, out of whom 31 had COVID-19. Other diagnoses included asthma, exacerbation of asthma and COPD, viral pneumonia, other respiratory tract infections, and cardiac conditions. In order to identify and diagnose COVID-19 from the samples, the team used Gas Chromatography (GC) - a procedure used for separating and analyzing compounds that can be vaporized without decomposition - and Ion Mobility Spectrometry (IMS) – an analytical technique used to separate and identify ionized molecules in the gas phase. The study participants gave a single breath-sample for the analysis of VOCs by GC-IMS. The analysis identified aldehydes (ethanal, octanal), ketones (acetone, butanone), and methanol that discriminated COVID-19 from other conditions.

“We are hugely encouraged by these findings. Employing tried and tested techniques used during the TOXI-Triage project, suggests that COVID-19 may be rapidly distinguished from other respiratory conditions,” said Paul Thomas, Professor of Analytical Science from Loughborough’s Department of Chemistry. “To develop this technique further larger studies are required, together with complementary GC-MS studies, to build on the data collected so far. If shown to be reliable, it offers the possibility for rapid identification or exclusion of COVID-19 in emergency departments or primary care that will protect healthcare staff, improve the management of patients and reduce the spread of COVID-19.”

Related Links:
Loughborough University


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A research team led by Prof. Hsing I-Ming (center), Professor of the Department of Chemical and Biological Engineering at HKUST, has developed TEMPO, a thermodynamically programmed one-pot CRISPR platform for rapid, point-of-care nucleic acid testing. Mr. Wu Xiaolong (third right) and Ms. Li Yanan (first left), PhD students from the Department of Chemical and Biological Engineering, are the co-first authors of this study. (Photo courtesy of HKUST)

Single-Tube CRISPR Test Detects Pathogens and Genetic Variants in 30 Minutes

Rapid, accurate detection of infectious agents and single-nucleotide variants remains difficult to deliver outside centralized laboratories. Although multi-step nucleic acid workflows are sensitive, they... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Journal Addresses Evolving Needs in Clinical and Translational Pathology

Clinical pathology underpins diagnosis and therapy selection across oncology and other major diseases, but the field is rapidly evolving as new technologies reshape how disease is studied and classified.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.